Bull
$115.77
Scenario price
$153.840
-3.754 (-2.44%)At close
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
Agilent Technologies is a good buy right now due to its recent strong financial performance, including a 7.3% core revenue growth in Q3 FY2026, and a current price of $153.84, which is below the average analyst price target of $180. The stock has a forward P/E ratio of 23.26, suggesting it is reasonably valued for future growth. The main risk is the recent 5-day price change of -3.25%, indicating short-term volatility.
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

Agilent Technologies Reports Strong Q3 FY2026 Results

Agilent Reports Third Quarter Net Income Growth

Nvidia Surges After Beating Q2 Expectations

Meta Reaches Settlement, Stock Gains Slightly

Nvidia Earnings Week Sparks Market Focus
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).
Agilent Technologies is a good buy right now due to its recent strong financial performance, including a 7.3% core revenue growth in Q3 FY2026, and a current price of $153.84, which is below the average analyst price target of $180. The stock has a forward P/E ratio of 23.26, suggesting it is reasonably valued for future growth. The main risk is the recent 5-day price change of -3.25%, indicating short-term volatility.
本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。